393 / 1266
Summary
• GBM exhibit multiple genetic abnormalities
• Inter- and intra-patient heterogeneity
• Targeting single pathways ineffective to date
• Tumour specificity essential
• Immunological/vaccine therapies have potential
• DNA damage response also a potential target